Challenge 5 Report

* There is a relatively weak correlation between tumor volume when the mice are on Capomulin and the weight of said mice. Regardless of the weight, we would want the tumor volumes to be decreasing with the drug regimens, right?
* When looking at the line chart, Capomulin does seem to be having an effect on the tumor size. We don’t know for sure that it is the drug regimen doing this, but the chart certainly suggests that.
* The box chart shows that between the selected drugs, there is still a large range of tumor sizes. This suggests that some of them don’t really work all that well (so far and in these conditions). The lower bounds though is surprisingly low. The Capomulin specific data suggests that it may be that drug lowering the bounds and outliers in that direction (which is what we would want to happen).
* Capomulin was also tested more by number than the others, so that may play a part in the wide range in the box chart. However, it isn’t tested *that* much more, so whatever effect this may have I would suspect is limited.
* When looking at the summary statistics by drug regimen, Capomulin certainly has the lowest sizes with the least variance and most consistent mean. This is useful information as long as the researchers made sure that the ‘starting point’ of each mouse id’s data was the same; that they all were exposed to cancer causing material in the exact same dose for the exact same amount of time.